{"entity":{"id":"nct07223424","kind":"trial","name":"Patient Preference for Subcutaneous vs. Intravenous Immune Therapy","aka":["PSI-Immune"],"tldr":"A phase 2 trial of nivolumab and pembrolizumab in colorectal cancer, run by Diwakar Davar, now recruiting.","summary":"Patient Preference for Subcutaneous vs. Intravenous Immune Therapy is a phase 2, randomised interventional study registered as NCT07223424 by Diwakar Davar, with a registry enrolment figure of 880 participants, started 2025-11-04 and due to reach its primary completion in 2030-11-30. Interventions recorded: nivolumab; pembrolizumab. Conditions listed: Renal Cell Carcinoma; Non Small Cell Lung Cancer; Melanoma; Colo-rectal Cancer (dMMR/MSI-H CRC); Hepatocellular Carcinoma; Ulcerative Colitis; Esophageal Cancer; Squamous Cell Carcinoma; Gastric/GEJ; Cervical Cancer; Gastro-Esophageal Adenocarcinoma; Esophageal Adenocarcinoma. Primary outcome: Preference for Subcutaneous Nivolumab Treatment; Preference for Subcutaneous Pembrolizumab Treatment. Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07223424","url":"https://clinicaltrials.gov/study/NCT07223424"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07223424","phase":"2","setting":"Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)","sponsor":"Diwakar Davar","enrolled":880,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07223424/","neighbours":{"cancer":[{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}